Table 4. Comparison of anti-EBV antibodies in different patients visiting the PUMC Hospital, Beijing, 2013–2017.
| Mean±SD or Age group(yr.) |
VCA IgG Pos no. (%) |
VCA IgM Pos no. (%) |
VCA IgA Pos no. (%) |
EA/D IgA Pos no. (%) |
EBNA1 IgG Pos no. (%) |
|
|---|---|---|---|---|---|---|
| NPC | 48.67 ±12.96 | 424(100) | 13(3.10) | 361(86.99) | 239(59.16) | 38(100) |
| non-NPC | 51–60y | 822(99.76) | 31(2.43) | 185(19.33) | 108(10.44) | 238(95.97) |
| χ2/P-value | 550.23/0.000* | 373.88/0.000 | ||||
| SLE(total) | 24.81 ±15.13 | 233(100) | 19(4.74) | 79(45.40) | 26(13.20) | 130(99.24) |
| non-NPC | 21–30y | 774(98.47) | 88(6.40) | 160(22.79) | 96(12.80) | 268(94.37) |
| χ2/P-value | 34.80/0.000 | |||||
| SLE(6-10y) ** | 8.47 ±1.69 | 52(100) | 1(2.00) | 25(59.52) | 7(14.89) | 34(100) |
| non-NPC& non-SLE(6-10y) *** | 8.12 ±1.46 | 377(82.50) | 54(11.13) | 67(18.41) | 32(8.49) | 192(75.89) |
| χ2/P-value | 9.52/0.002 | 34.02/0.000 | 9.02/0.003 | |||
| Other Autoimmune Diseases (Non-SLE) | 37.13 ±19.89 | 366(95.31) | 29(4.04) | 75(25.60) | 29(8.98) | 149(91.41) |
| non-NPC | 31–40y | 811(98.78) | 39(3.07) | 182(19.72) | 97(9.67) | 199(94.76) |
| χ2/P-value | 4.27/0.039 | |||||
| CNS neuropathy | 40.21 ±19.0 | 77(98.72) | 0(0/104) | 14(24.06) | 7(13.46) | 20(90.91)) |
| non-NPC | 41–50y | 759(99.73) | 35(2.98) | 170(15.15) | 109(9.67) | 189(97.42) |
* Results of comparison of VCA IgA between NPC patients (upper line) and non-NPC patients (lower line), same patterns were used for other comparisons in table 4.
**SLE(6–10y): SLE patients between 6 and 10 years old were chosen for comparison as there was only one SLE patient under 6 years old.
*** Non-NPC & non-SLE (6–10y): All 6–10 years old patients in whom NPC and SLE were excluded.